Abstract 142P
Background
Liquid biopsy is an emerging technology capable of detecting cancer, while CT-imaging is the gold standard. We aim to correlate imaging features from CT-scans to liquid biopsy ctDNA tumor fraction (TF) and blood Tumor Mutational Burden (bTMB).
Methods
This retrospective multicentric study included 1017 patients with metastatic cancer who underwent a variety of treatments. Liquid biopsy and contemporaneous CT-scans were collected. TF and bTMB values were computed using FoundationOne Liquid CDX solution by Roche, with high tumor fraction being over 10%. Two expert radiologists outlined all cancerous lesions in the largest axial diameter. Total tumor volume (TTV) was defined as the sum of estimated lesion volumes. Training set consisted of data from several imaging centers, while the validation set was single-center. Continuous value distributions by category were tested using the Mann-Whitney U-test, and a threshold was set with ROC curve analysis using Youden's Index. This cutoff defined high and low groups, and a Χ2 test of independence was used to examine the correlation. Sensitivity and specificity were reported with imaging features taken as the gold standard. Subanalyses were run on patients with liver lesions.
Results
Overall, 55294 lesions were annotated, most commonly located in the lung (n=20074), liver (n=11297) and lymph nodes (n=10222). The train and validation sets included 599 and 418 patients. Preliminary analyses were performed on the train set. Patients with low TF had significantly less TTV than those with high TF (p<0.001). ROC analysis yielded an AUC of 0.63 with a threshold of 106 cm3. Correlation was significant between TTV and TF categories (Χ2 test: p<0.001). The sensitivity and specificity were 76% and 42%. For patients with liver lesions (n=253) , TTV threshold was 108 cm3 with an AUC of 0.66. Correlation was significant between TTV and TF categories (Χ2 test: p<0.001). The sensitivity and specificity were 82% and 42%.
Conclusions
Analysis showed significant correlation between TTV and ctDNA TF. Sensitivity was higher for patients with liver lesions, suggesting that some organs shed tumoral DNA more than others. The study of tumor heterogeneity on imaging and its correlation to bTMB is in progress.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
134P - TERT-associated DNA polymerases genes link CAF and CD8+ T cells to improve immunotherapy response rate across multiple cancers
Presenter: Zhiwen Luo
Session: Poster session 01
135P - The lymphocyte stability index (LSI) forms a pan-cancer peripheral biomarker for overall survival post initiation of immune checkpoint blockade (ICB)
Presenter: Robert Watson
Session: Poster session 01
136P - Pembrolizumab in patients of Chinese descent with microsatellite instability-high/mismatch repair deficient advanced solid tumors: KEYNOTE-158
Presenter: Yimin Mao
Session: Poster session 01
137P - VEGFR-3 expression profiling by histology and mRNA signature to classify patient population for the selective VEGFR-3 inhibitor EVT801
Presenter: Carlos Gomez-Roca
Session: Poster session 01
138P - Precision medicine phase II study evaluating the efficacy of olaparib in patients with progressive solid cancers and carriers of homologous recombination repair genes alterations
Presenter: Marie Polito
Session: Poster session 01
139P - The characteristics in Chinese NSCLC patients with different BRAF mutation classes
Presenter: Qian Wang
Session: Poster session 01
140P - Colorectal adenoma subtypes exhibit distinct molecular profiles- implications to early detection
Presenter: Francesco Mancuso
Session: Poster session 01
141P - Microsatellite instability and its relationship with systemic inflammation as prognostic factors in localised colorectal cancer
Presenter: Ja Hyun Yeo
Session: Poster session 01
143P - Is liquid biopsy a good tool for microsatellite instability (MSI) assessment in solid tumors?
Presenter: Julieta Rodriguez
Session: Poster session 01
144P - Artificial intelligence supported treatment decisions for precision oncology
Presenter: Damian Rieke
Session: Poster session 01